178 related articles for article (PubMed ID: 36913038)
1. Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
Muñoz-Vendrell A; Arroyo-Pereiro P; León I; Bau L; Matas E; Martínez-Yélamos A; Martínez-Yélamos S; Romero-Pinel L
J Neurol; 2023 May; 270(5):2559-2566. PubMed ID: 36913038
[TBL] [Abstract][Full Text] [Related]
2. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
[TBL] [Abstract][Full Text] [Related]
3. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
4. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
5. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
7. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
[TBL] [Abstract][Full Text] [Related]
8. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
10. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
12. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review.
Brown JD; Muston BT; Massey J
Mult Scler Relat Disord; 2024 Jun; 86():105605. PubMed ID: 38640586
[TBL] [Abstract][Full Text] [Related]
13. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
[TBL] [Abstract][Full Text] [Related]
14. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
15. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
16. Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.
Sgarlata E; Chisari CG; Toscano S; Finocchiaro C; Lo Fermo S; Millefiorini E; Patti F
Curr Neuropharmacol; 2022; 20(10):1978-1987. PubMed ID: 34766895
[TBL] [Abstract][Full Text] [Related]
17. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
18. Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
Evdoshenko E; Stepanova A; Shumilina M; Davydovskaya M; Khachanova N; Neofidov N; Kalinin I; Popova E; Dubchenko E; Pozhidaeva N; Volkov A; Sivertseva S; Prilenskaya A; Malkova N; Korobko D; Vergunova I; Shchur S; Makshakov G
PLoS One; 2019; 14(5):e0217303. PubMed ID: 31136608
[TBL] [Abstract][Full Text] [Related]
19. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
Mathew T; Kamath V; John SK; Netravathi M; Iyer RB; Raghavendra S; Kumar S; Neeharika ML; Gupta S; Murgod U; Shivakumar R; Annadure RK; Ichaporia N; Rohatgi A; Nair SS; Yareeda S; Anand B; Singh P; Renukaradhya U; Arulselvan V; Reddy YM; Surya N; Sarma GRK; Nadig R; Deepalam S; Sharath Kumar GG; Satishchandra P; Singhal BS; Parry G
Mult Scler Relat Disord; 2022 Oct; 66():104059. PubMed ID: 35908446
[TBL] [Abstract][Full Text] [Related]
20. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
